Syndelic Saga: The Fight for Psychedelic Product Integrity 

In September of 2025, a report compiled by researchers from Oregon State University made waves across the media landscape. The report found that 12 out of 12 chocolate and gummy products sold in Portland area retail stores and advertising  “magic mushrooms” in their ingredients, returned zero traces of psilocybin across the board. They also tested negative for muscimol, the principal psychoactive constituent of Amanita mushrooms.

Laboratory analysis revealed that the sampled products did contain kavalactones, derived from kava, an ethnomedicinal shrub native to the Polynesian islands. They also contained hemp extracts, and various combinations and concentrations of “syndelics,” an emergent class of synthetic psychoactive compounds. These compounds are inspired by the molecular structures of classic serotonergic psychedelics like psilocybin and LSD – and designed to mimic their functions.

Last week, this trend caught the attention of California health authorities as the internationally distributed syndelic-containing “magic mushroom” brand Tre House came under the scrutiny of the California Department of Public Health. This move signals a growing awareness among authorities and regulators about legal loopholes exploited by manufacturers in the unregulated psychedelic product market. The company did not reply to a request for comment. 

Given the criminal penalties tied to the current Schedule 1 status of psilocybin, LSD, DMT, and other psychedelic compounds under the Controlled Substances Act – and the current meteoric rise in popularity of these drugs despite their illicit status – this new class of “Syndelic” products have emerged to meet market demand without exposing manufacturers to the legal risks incurred by offering the actual substances these designer drugs are created to imitate. 

The resulting market conditions are a “cat and mouse” game where manufacturers are financially incentivized to obfuscate the active ingredients in their products while capitalizing on public interest and consumer unawareness. These products use psychedelic forward packaging, emblazoned with suggestive branding and phrases like “Trippy Compounds” or “Proprietary Mushroom Blend,” without disclosing what is actually in the product. 

Products marketed like this are found on gas station shelves, in smoke shops, and at a hundred other points of sale. They can also be found on anonymous online marketplaces, often staying available until health authorities intervene – a crackdown that may be imminent for compounds with a rising profile, like 4-acetoxy-DET and 4-acetoxy-DMT, found in the Tre House products.

“It’s music to my ears that the opportunists are being exposed and consumer awareness is growing,” says Joe Robinson, founder of psychedelic product integrity watchdog and education service PsiloSafe.

“Deceptive labeling does not help anyone except the greedy brands that are misrepresenting in the name of profits,” says Robinson. “Imagine buying a bottle of vodka and finding out there was methanol alcohol in it? In the case of TRE House, the front of the package specifically says mushrooms and ‘natural product,’ but the lab results are saying otherwise.”

Promoting The Products

Platforms like TikTok have amplified public interest in these types of products due to creators sharing their unhinged experiences with them and uploading promotional videos. Some of these “trippy” consumer packaged goods have even made it onto the wildly popular TikTok Shop, which can ship out tens of thousands of units before being flagged and taken down.

Creators earn paid commission every time someone purchases one of the products through the link provided on their video – even though it’s evident that many of the creators themselves have no idea what’s actually in the product. 

“The ‘Psychedelic Renaissance’ has ushered in a new wave of products such as mushroom chocolates and gummies, as well as their synthetic counterparts. These products are often adorned with colorful graphics and genius branding; to each their own, but I personally prefer to stay true to the fruit, and far from the psychedelic candy and synthetics,” says music industry executive and high-dose mushroom ceremonialist Edward Crowe, echoing the sentiments of many in the mushroom space. 

“Respect is the keyword in my mushroom world. I often go to the mushroom for guidance, but it’s equally important to me that I bring value to the mushroom through integration and living up to the profound feelings and ideas of transformation that we experience during the trip, and make sure to allow them to take shape in your reality. These synthetic candies will never give you that.” 

Confusing Legislation

The confusing patchwork of psychedelic legislation across the U.S. and internationally adds a further layer of complexity and confusion. I came across a video on TikTok where a lawyer in Ohio discussed a recent case involving an Ohio man who was sentenced to six months in jail for possession of a mushroom chocolate that he allegedly “legally bought in Michigan” and brought back to Ohio. 

In truth, mushroom chocolates are not legal to buy in Michigan, or anywhere in the U.S. for that matter. Mushrooms are decriminalized in certain cities in Michigan and elsewhere, and there are frameworks for legal, regulated access in Colorado and Oregon, but mushroom chocolates are not legally, commercially available for over-the-counter purchase anywhere in the U.S., according to federal law. 

There have even been anecdotal reports of product manufacturers themselves contacting functional mushroom product purveyors, wanting to create their own white-label psilocybin mushroom microdosing products. They are doing this in response to their own customers’ inquiries, only to be dumbfounded when they find out that psilocybin mushroom microdoses aren’t actually legal. The market demand, cultural adoption, and confusing policy patchwork – exacerbated by media hype – is so bewildering that the general public is largely unaware of the legal status quo of mushrooms and psychedelics in their home jurisdictions. 

Beyond the profiteering angle, egregious potential civil and criminal penalties tied to providing immediate and affordable access to actual psilocybin mushrooms and other psychedelic compounds, incentivize some manufacturers to not disclose the active psychedelic ingredients in their products. 

Beyond active ingredients, dosing recommendations are also typically wildly ambiguous and skewed. Many products use a cartoonish diagram equating serving sizes to abstract concepts such as: “1-2 squares of chocolate = Microdose, 3-4 = Recreational, 5 + = Cosmic.”

This approach can lead to bewilderment, confusion, and a lack of consistency, even if the products do actually contain psilocybin mushrooms. There’s also the fact that psilocybin potency varies wildly across strains and even within the same batch of the same mushroom. As a result, “4 grams of magic” does not translate across the product landscape. 

This is where “psilocin equivalent” is a more effective dosing guideline than listing the number of grams of psilocybin mushrooms. Psilocin equivalent refers to the actual amount of psychoactive substance that someone will ingest when they consume a product containing psilocybin, as psilocybin is broken down into psilocin after ingestion. As such, psilocin is approximately 1.4 times more potent than psilocybin per gram, meaning that a more accurate dosing guide should include the psilocin equivalent measurement on the packaging. 

The antidote to misinformation and disinformation is clear: transparent education and protocols designed to curtail predatory and misleading practices in both the unregulated and regulated market. Until a more sustainable and intelligent policy framework is enacted for psychedelics that incorporates decriminalization as a hedge against the white and black binary of prohibition, as well as the costly, exclusive, and still largely hypothetical medical access model, unscrupulous manufacturers will continue to stay one step ahead of legislation by meeting consumer demand with synthetic and unscheduled analogues without disclosing their presence on the packaging. 

Until we do see sensible policy change – if that day ever comes – it’s up to stakeholders in the unregulated market themselves to enact self-regulation through labeling integrity, active ingredient disclosures, and accurate dosing information couched within a framework of mutual interest and community spirit.